Thymosin Alpha-1

Beskrivelse

Thymosin Alpha-1 (Tα1, Thymalfasin, or Zadaxin) is a synthetic 28-amino acid peptide identical to the naturally occurring thymic hormone fragment that plays a key role in immune regulation. Derived from prothymosin alpha, Tα1 modulates, enhances, and restores immune function by stimulating T-cell differentiation and maturation, increasing CD4+ T-cell counts and CD4+/CD8+ ratios, boosting natural killer cell activity, promoting dendritic cell and macrophage function, and balancing pro- and anti-inflammatory responses without overstimulating the immune system. Clinically, Thymosin Alpha-1 (under brand names like Zadaxin) has been used for decades in various countries as an immune adjuvant in chronic viral infections (e.g., hepatitis B/C), immunocompromised states, cancer immunotherapy support, sepsis, severe acute pancreatitis, and other conditions involving immune suppression or dysregulation. Research highlights its ability to improve vaccine responses (including in older adults or immunocompromised individuals), reduce infection risk, alleviate inflammation, enhance antiviral and antitumor immunity, and support recovery in critical illnesses. In wellness, anti-aging, and regenerative medicine contexts, Tα1 is explored for bolstering overall immune resilience, reducing chronic inflammation, aiding recovery from illness or stress, and potentially supporting longevity through immune restoration. Typical administration involves subcutaneous injection (standard doses often 1.6 mg twice weekly or 1.6–3.2 mg daily in research/clinical settings, adjusted per protocol), with cycles varying from weeks to months under medical oversight and monitoring of immune markers (e.g., CD4/CD8 ratios, cytokine profiles). Clinical studies and meta-analyses show favorable safety, with common side effects limited to mild injection-site reactions, transient fatigue, or rare flu-like symptoms; serious adverse events are uncommon, and it generally exhibits a strong safety profile even in long-term use. While approved in certain regions (e.g., as Zadaxin for specific indications like hepatitis or as an immune enhancer), Thymosin Alpha-1 is not universally FDA-approved for broad therapeutic uses in the US as of 2026—availability often occurs through compounding pharmacies for off-label or investigational applications, requiring prescription and professional supervision. It is contraindicated in hypersensitivity cases and used cautiously in autoimmune conditions where immune stimulation could exacerbate symptoms (though it often modulates rather than overactivates). Always consult a qualified healthcare provider before starting Thymosin Alpha-1 for thorough evaluation, personalized dosing, immune monitoring, and integration into a comprehensive health plan including lifestyle factors. Thymosin Alpha-1 offers a targeted, evidence-supported approach to immune optimization when benefits outweigh risks.